XML 48 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Note 1 - Significant Accounting Policies and Concentrations of Risk - Cumulative Effective Adopted Accounting Pronouncement (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Deferred collaboration expense $ 9       $ 210       $ 9 $ 210   $ 152
Deferred revenue 221       8,484       221 8,484   7,300
Accumulated deficit (731,969)       (631,843)       (731,969) (631,843)   (630,717)
Revenues 2,729 $ 1,454 $ 12,494 $ 3,976 3,890 $ 8,760 $ 3,099 $ 9,437 20,653 25,186 $ 26,353  
Research and development                 84,888 66,962 61,008  
Net loss $ (27,432) $ (29,597) $ (18,446) $ (25,777) $ (19,543) $ (15,134) $ (16,886) $ (14,219) $ (101,252) $ (65,782) $ (55,144)  
Basic and diluted net loss per common share (in dollars per share) $ (0.25) $ (0.28) $ (0.19) $ (0.26) $ (0.20) $ (0.18) $ (0.21) $ (0.19) $ (0.98) $ (0.78) $ (0.75)  
Accounting Standards Update 2014-09 [Member]                        
Deferred collaboration expense                       (58)
Deferred revenue                       (1,184)
Accumulated deficit                       $ 1,126
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]                        
Deferred collaboration expense                    
Deferred revenue                    
Accumulated deficit                    
Research and development                 58      
Net loss                 $ 1,126      
Basic and diluted net loss per common share (in dollars per share)                 $ 0.01      
Calculated under Revenue Guidance in Effect before Topic 606 [Member]                        
Deferred collaboration expense 9               $ 9      
Deferred revenue 221               221      
Accumulated deficit $ (731,969)               (731,969)      
Research and development                 84,946      
Net loss                 $ (100,126)      
Basic and diluted net loss per common share (in dollars per share)                 $ (0.97)      
Collaborative and Other Research and Development [Member]                        
Revenues                 $ 14,552 $ 13,142 $ 14,402  
Collaborative and Other Research and Development [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]                        
Revenues                 1,184      
Collaborative and Other Research and Development [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member]                        
Revenues                 $ 15,736